Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
Press releases | GSK US
WEBUS FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
WEB4 days ago · J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares closed yesterday at p1,497.25.
GSK delivers continued strong performance and upgrades 2024 …
WEBJul 31, 2024 · Broad-based performance drives sales, core profit and core EPS growth: Total Q2 2024 sales £7.9 billion +13%. Vaccines sales +1%, +3% ex COVID. Shingrix £0.8 billion -4%.
GlaxoSmithKline News | GSK News - NewsNow
WEBNewsNow aims to be the world's most accurate and comprehensive aggregator of GlaxoSmithKline news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications.
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
WEB6 hours ago · LONDON, Oct 7 (Reuters) - Pfizer (PFE.N), opens new tab on Monday won a bid in a London court to invalidate two of GSK's (GSK.L), opens new tab patents relating to a respiratory syncytial virus ...
GSK's experimental drug shows promise in reducing severe …
WEBMay 21 (Reuters) - GSK's (GSK.L) experimental drug met its primary goal of reducing asthma attacks in a late-stage trial, marking a bright spot for a treatment that the British drugmaker...
GSK raises profit outlook on strong vaccine, HIV drug sales
WEBMay 1, 2024 · GSK raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV medicines, though it expects sales growth to slow in the second half.
GSK News
WEBGSK News